Reva Medical’s Fantom bioresorbable scaffold succeeds in two-year trial

Reva Medical (ASX:RVA) touted sustained safety and efficacy results for its Fantom bioresorbable scaffold at this year’s EuroPCR meeting.

The company also revealed new information about its suite of Fantom Encore products, noting that the devices will have strut profiles of 95 microns, 105 microns and 115 microns.

Get the full story at our sister site, Drug Delivery Business News.

The post Reva Medical’s Fantom bioresorbable scaffold succeeds in two-year trial appeared first on MassDevice.

from MassDevice https://ift.tt/2s5Zoxw